TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prospective, Randomized, Multi-Center Trial of Initial Trophic Enteral Feeding Followed by Advancement to Full-Calorie Enteral Feeding vs. Early Advancement to Full-Calorie Enteral Feeding in Patients With Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome (ARDS)
Brief Summary: Acute respiratory distress syndrome (ARDS) and acute lung injury (ALI) are medical conditions that occur when there is severe inflammation and increased fluids in both lungs, making it difficult for the lungs to function properly. Hospital treatment for a person with ALI/ARDS often includes the use of a breathing machine, or ventilator, until the person is able to breathe without assistance. Initiating proper nutrition through a feeding tube early in a person's hospital stay may help to improve recovery, but the optimal timing, composition, and amount of feeding treatments remain unknown. This study will evaluate whether early or delayed full-calorie feeding through a feeding tube is more effective in reducing recovery time and increasing survival rates in people with ALI/ARDS.


Options:
A: Arm Label: Full enteral feeding; Type: ACTIVE_COMPARATOR; Interventions: Other: Initial enteral feeding | Arm Label: Modified full enteral feeding; Type: EXPERIMENTAL; Interventions: Other: Initial enteral feeding, Drug: metoclopramide or mosapride | Arm Label: Permissive underfeeding; Type: EXPERIMENTAL; Interventions: Other: Initial enteral feeding | Intervention Type: OTHER; Name: Initial enteral feeding; Assigned to Arm(s): Full enteral feeding, Modified full enteral feeding, Permissive underfeeding | Intervention Type: DRUG; Name: metoclopramide or mosapride; Assigned to Arm(s): Modified full enteral feeding
B: Arm Label: TARGET protocol EN 1.5 kcal/mL; Type: EXPERIMENTAL; Interventions: Dietary Supplement: TARGET protocol EN 1.5 kcal/mL | Arm Label: TARGET protocol EN 1.0 kcal/mL; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: TARGET protocol EN 1.0 kcal/mL | Intervention Type: DIETARY_SUPPLEMENT; Name: TARGET protocol EN 1.5 kcal/mL; Assigned to Arm(s): TARGET protocol EN 1.5 kcal/mL | Intervention Type: DIETARY_SUPPLEMENT; Name: TARGET protocol EN 1.0 kcal/mL; Assigned to Arm(s): TARGET protocol EN 1.0 kcal/mL
C: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Minimal (Trophic) Feeding | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Full Feeding | Intervention Type: BEHAVIORAL; Name: Minimal (Trophic) Feeding; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Full Feeding; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Program Evaluation of New York City Health eHearts Pay for Quality Program
Brief Summary: Do monetary incentives in small independent primary care practices improve the delivery of preventive services as recommended by U.S. Preventive Services Task Force (USPSTF) guidelines for cardiovascular health?


Options:
A: Arm Label: Full Smoking Cessation Treatment Coverage (100%); Type: OTHER; Interventions: Other: Full Smoking Cessation Treatment Coverage (100%) | Arm Label: No Smoking Cessation Treatment Coverage (0%); Type: OTHER; Interventions: Other: No Smoking Cessation Treatment Coverage (0%) | Intervention Type: OTHER; Name: Full Smoking Cessation Treatment Coverage (100%); Assigned to Arm(s): Full Smoking Cessation Treatment Coverage (100%) | Intervention Type: OTHER; Name: No Smoking Cessation Treatment Coverage (0%); Assigned to Arm(s): No Smoking Cessation Treatment Coverage (0%)
B: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A | Arm Label: 3; Type: N/A; Interventions: N/A | Arm Label: 4; Type: N/A; Interventions: N/A | Arm Label: 5; Type: N/A; Interventions: N/A | Arm Label: 6; Type: N/A; Interventions: N/A
C: Arm Label: Standard Care (SC); Type: EXPERIMENTAL; Interventions: Behavioral: Standard Care (SC) | Arm Label: Intensive Counseling (IC); Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Counseling (IC) | Intervention Type: BEHAVIORAL; Name: Standard Care (SC); Assigned to Arm(s): Standard Care (SC) | Intervention Type: BEHAVIORAL; Name: Intensive Counseling (IC); Assigned to Arm(s): Intensive Counseling (IC)
D: Arm Label: patch; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Arm Label: nicotine lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine lozenge | Arm Label: bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion | Arm Label: patch + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: patch + lozenge | Arm Label: buproion + lozenge; Type: ACTIVE_COMPARATOR; Interventions: Drug: bupropion + lozenge | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): patch | Intervention Type: DRUG; Name: nicotine lozenge; Assigned to Arm(s): nicotine lozenge | Intervention Type: DRUG; Name: bupropion; Assigned to Arm(s): bupropion | Intervention Type: DRUG; Name: patch + lozenge; Assigned to Arm(s): patch + lozenge | Intervention Type: DRUG; Name: bupropion + lozenge; Assigned to Arm(s): buproion + lozenge

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer
Brief Summary: The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles where a gonadotrophin-releasing hormone (GnRH) antagonist was used for prevention of premature luteinizing hormone (LH) surge and where a single embryo was transferred at the blastocyst stage.


Options:
A: Arm Label: Highly Purified Menotrophin; Type: EXPERIMENTAL; Interventions: Drug: Highly purified menotrophin | Arm Label: Recombinant FSH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Recombinant FSH | Intervention Type: DRUG; Name: Highly purified menotrophin; Assigned to Arm(s): Highly Purified Menotrophin | Intervention Type: DRUG; Name: Recombinant FSH; Assigned to Arm(s): Recombinant FSH
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Intervention Type: DRUG; Name: Follitropin Delta (FE 999049); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Follitropin Alfa (GONAL-F); Assigned to Arm(s): B
C: Arm Label: CONSORT Dosing; Type: EXPERIMENTAL; Interventions: Drug: GONAL f® prefilled pen | Arm Label: Standard Dosing; Type: ACTIVE_COMPARATOR; Interventions: Drug: GONAL f® prefilled pen | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): CONSORT Dosing | Intervention Type: DRUG; Name: GONAL f® prefilled pen; Assigned to Arm(s): Standard Dosing
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: D; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Intervention Type: DRUG; Name: Follitropin Delta (FE 999049); Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: Follitropin Alfa (GONAL-F); Assigned to Arm(s): B, D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Open-label, Assessor-blind, Parallel Groups, Multicentre Trial Comparing the Efficacy of MENOPUR Versus Recombinant FSH in Controlled Ovarian Stimulation Following a GnRH Antagonist Protocol and Single Embryo Transfer
Brief Summary: The main purpose of this clinical research trial was to compare the ongoing pregnancy rate between two gonadotrophins for controlled ovarian stimulation (MENOPUR and recombinant follicle-stimulating hormone (FSH)), in cycles where a gonadotrophin-releasing hormone (GnRH) antagonist was used for prevention of premature luteinizing hormone (LH) surge and where a single embryo was transferred at the blastocyst stage.


Options:
A: Arm Label: 450 IU daily dose of gonadotrophin; Type: ACTIVE_COMPARATOR; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Arm Label: 600 IU daily dose of gonadotrophin; Type: EXPERIMENTAL; Interventions: Drug: menotropins for injection, Drug: urofollitropin for injection | Intervention Type: DRUG; Name: menotropins for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin | Intervention Type: DRUG; Name: urofollitropin for injection; Assigned to Arm(s): 450 IU daily dose of gonadotrophin, 600 IU daily dose of gonadotrophin
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Follitropin Delta (FE 999049) | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Follitropin Alfa (GONAL-F) | Intervention Type: DRUG; Name: Follitropin Delta (FE 999049); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Follitropin Alfa (GONAL-F); Assigned to Arm(s): B
C: Arm Label: AMH-group; Type: EXPERIMENTAL; Interventions: Other: AMH-analysis | Arm Label: Non-AMH-group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: AMH-analysis; Assigned to Arm(s): AMH-group
D: Arm Label: Highly Purified Menotrophin; Type: EXPERIMENTAL; Interventions: Drug: Highly purified menotrophin | Arm Label: Recombinant FSH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Recombinant FSH | Intervention Type: DRUG; Name: Highly purified menotrophin; Assigned to Arm(s): Highly Purified Menotrophin | Intervention Type: DRUG; Name: Recombinant FSH; Assigned to Arm(s): Recombinant FSH

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Randomized Comparison of Localized Heat Therapy Versus Sodium Stibogluconate (Pentostam) for the Treatment of Old World Cutaneous Leishmaniasis (HSRRB Log No. A-12364)
Brief Summary: This study serves to compare the effectiveness of treating cutaneous leishmaniasis with either intravenous sodium stibogluconate or direct heat therapy using the ThermoMed-TM device.


Options:
A: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device
B: Intervention Type: DRUG; Name: Amphotericin B deoxycholate given as daily administration; Assigned to Arm(s): N/A
C: Arm Label: IL SSG; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium Stibogluconate | Arm Label: ETC+MWT; Type: EXPERIMENTAL; Interventions: Procedure: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: MWT; Type: EXPERIMENTAL; Interventions: Drug: DAC N-055 | Intervention Type: PROCEDURE; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC+MWT | Intervention Type: DRUG; Name: Sodium Stibogluconate; Assigned to Arm(s): IL SSG | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC+MWT, MWT
D: Arm Label: WR 279,396; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: WR 279,396; Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I/II Randomized Comparison of Localized Heat Therapy Versus Sodium Stibogluconate (Pentostam) for the Treatment of Old World Cutaneous Leishmaniasis (HSRRB Log No. A-12364)
Brief Summary: This study serves to compare the effectiveness of treating cutaneous leishmaniasis with either intravenous sodium stibogluconate or direct heat therapy using the ThermoMed-TM device.


Options:
A: Arm Label: Sodium stibogluconate intravenous; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium stibogluconate (Pentostam) | Arm Label: ThermoMed device; Type: EXPERIMENTAL; Interventions: Device: ThermoMed | Intervention Type: DRUG; Name: Sodium stibogluconate (Pentostam); Assigned to Arm(s): Sodium stibogluconate intravenous | Intervention Type: DEVICE; Name: ThermoMed; Assigned to Arm(s): ThermoMed device
B: Arm Label: ETC + DAC N-055; Type: EXPERIMENTAL; Interventions: Other: Electro-thermo-coagulation, Drug: DAC N-055 | Arm Label: ETC + physiological saline; Type: ACTIVE_COMPARATOR; Interventions: Other: Electro-thermo-coagulation, Drug: saline | Intervention Type: OTHER; Name: Electro-thermo-coagulation; Assigned to Arm(s): ETC + DAC N-055, ETC + physiological saline | Intervention Type: DRUG; Name: DAC N-055; Assigned to Arm(s): ETC + DAC N-055 | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): ETC + physiological saline
C: Arm Label: WR 279,396; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: WR 279,396; Assigned to Arm(s): WR 279,396 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: WR 279,396 Topical Treament; Type: EXPERIMENTAL; Interventions: Drug: WR 279,396 topical cream | Arm Label: Paromomycin Alone Topical treatment; Type: EXPERIMENTAL; Interventions: Drug: Paromomycin Alone topical cream | Arm Label: Vehicle Placebo Cream; Type: PLACEBO_COMPARATOR; Interventions: Drug: Vehicle placebo cream | Intervention Type: DRUG; Name: WR 279,396 topical cream; Assigned to Arm(s): WR 279,396 Topical Treament | Intervention Type: DRUG; Name: Paromomycin Alone topical cream; Assigned to Arm(s): Paromomycin Alone Topical treatment | Intervention Type: DRUG; Name: Vehicle placebo cream; Assigned to Arm(s): Vehicle Placebo Cream

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effectiveness of Chest Physiotherapy Actual Versus Conventional Techniques in Infants With Acute Viral Bronchiolitis. Random Clinical Trial
Brief Summary: The purpose of this study is to verify the effectiveness of chest physiotherapy (actual versus conventional) on respiratory distress in infants with acute viral bronchiolitis.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Procedure: Chest Physiotherapy with Forced Expiratory Technique | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Nasopharyngeal Aspiration | Intervention Type: PROCEDURE; Name: Chest Physiotherapy with Forced Expiratory Technique; Assigned to Arm(s): A | Intervention Type: PROCEDURE; Name: Nasopharyngeal Aspiration; Assigned to Arm(s): B
B: Arm Label: Rhinopharyngeal clearance + 0.9% saline; Type: EXPERIMENTAL; Interventions: Procedure: Rhinopharyngeal clearance, Other: 0.9% saline | Arm Label: Aspiration + 0.9% saline; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Aspiration, Other: 0.9% saline | Intervention Type: PROCEDURE; Name: Rhinopharyngeal clearance; Assigned to Arm(s): Rhinopharyngeal clearance + 0.9% saline | Intervention Type: PROCEDURE; Name: Aspiration; Assigned to Arm(s): Aspiration + 0.9% saline | Intervention Type: OTHER; Name: 0.9% saline; Assigned to Arm(s): Aspiration + 0.9% saline, Rhinopharyngeal clearance + 0.9% saline
C: Arm Label: Manual maneuvers physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Manual maneuvers physiotherapy group | Arm Label: High frequency compression chest wall; Type: EXPERIMENTAL; Interventions: Other: High frequency compression of the chest wall group, Other: Manual maneuvers physiotherapy group | Intervention Type: OTHER; Name: High frequency compression of the chest wall group; Assigned to Arm(s): High frequency compression chest wall | Intervention Type: OTHER; Name: Manual maneuvers physiotherapy group; Assigned to Arm(s): High frequency compression chest wall, Manual maneuvers physiotherapy
D: Arm Label: 1- Conventional Chest Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy - Conventional | Arm Label: 2- Chest physiotherapy- Actual techniques; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Chest physiotherapy - actual techniques | Arm Label: 3- Airway Suction; Type: ACTIVE_COMPARATOR; Interventions: Procedure: 3-Airway suction | Intervention Type: PROCEDURE; Name: Chest physiotherapy - Conventional; Assigned to Arm(s): 1- Conventional Chest Physiotherapy | Intervention Type: PROCEDURE; Name: Chest physiotherapy - actual techniques; Assigned to Arm(s): 2- Chest physiotherapy- Actual techniques | Intervention Type: PROCEDURE; Name: 3-Airway suction; Assigned to Arm(s): 3- Airway Suction

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: This is a multi-center, open-label, non-controlled Pilot Study. Approximately 24 patients will be assigned to one of 3 treatment groups (8 patients each group). Patients in each group will receive 2, 4, and 6 (3 followed by a retreatment of 3) subsegmental treatments, respectively. All patients will receive treatment in a single lung under conscious sedation or general anesthesia. Patients will be followed for 24 weeks after completion of PLVR treatment(s). Upon completion of 12-week follow-up, all safety and efficacy data will be analyzed to determine an effective treatment dose. Thereafter, Group 1 patients may elect to be retreated at additional sites so that their total dose received is consistent with the effective dose. All study patients will receive standard medical therapy in addition to PLVR.


Options:
A: Arm Label: Treatment plus Optimal Medical Therapy; Type: EXPERIMENTAL; Interventions: Device: InterVapor® treatment plus Optimal Medical Therapy | Arm Label: Optimal Medical Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Optimal Medical Therapy | Intervention Type: DEVICE; Name: InterVapor® treatment plus Optimal Medical Therapy; Assigned to Arm(s): Treatment plus Optimal Medical Therapy | Intervention Type: OTHER; Name: Optimal Medical Therapy; Assigned to Arm(s): Optimal Medical Therapy
B: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx's) | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx's); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC)
C: Arm Label: PLVR; Type: EXPERIMENTAL; Interventions: Device: Polymeric Lung Volume Reduction System (PLVR) | Intervention Type: DEVICE; Name: Polymeric Lung Volume Reduction System (PLVR); Assigned to Arm(s): PLVR
D: Arm Label: Endobronchial valve:; Type: EXPERIMENTAL; Interventions: Device: Endobronchial valve | Intervention Type: DEVICE; Name: Endobronchial valve; Assigned to Arm(s): Endobronchial valve:

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone Cognitive-behavioral Therapy for Subthreshold Depression and Presenteeism in Workplace: a Randomized Controlled Trial
Brief Summary: The purpose of the study is to examine the effectiveness of telephone cognitive-behavioral therapy for subthreshold depression and presenteeism in workplace, in comparison with treatment-as-usual (TAU) (which is minimal contact through Employers Assistance Program (EAP)).


Options:
A: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
B: Arm Label: CBT; Type: EXPERIMENTAL; Interventions: Behavioral: CBT, Behavioral: EAP | Arm Label: TAU; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: EAP | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT | Intervention Type: BEHAVIORAL; Name: EAP; Assigned to Arm(s): CBT, TAU
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Mindfulness Based Cognitive Therapy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Enhancement Program and medication management | Intervention Type: BEHAVIORAL; Name: Mindfulness Based Cognitive Therapy; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Health Enhancement Program and medication management; Assigned to Arm(s): 2
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: B